Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
703 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Efficacy and Safety of Biosimilar Ranibizumab (OPTIMAB®) versus Innovator Ranibizumab in Patients with Neovascular (Wet) Age-Related Macular Degeneration: A Double-Blind, Randomized, Multicenter, Phase III Study.
Rana PJ, Deshmukh H, Shah U, Kumar V, Kanungo S, Singhal D, Mahapatra SK, Vakharia I, Jaiswal M, Gondane A, Vaidya P, Shahavi V, Shandilya H, Pawar D, Sharma A. · Clin Ophthalmol · 2024 · cited 4 timesOpen accessclinical trial, case reports
- Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study.
Gao Y, Lu F, Li X, Dai H, Liu K, Liu X, Sun Z, Xiang J, Ding L, Liang C, Wang Y, Shen Z, Zhang M. · Eye (Lond) · 2023 · cited 6 timesOpen accessresearch support, non-u.s. gov't, multicenter study
- Performance of Deep Learning in Classifying Age-Related Macular Degeneration From Images: Systematic Review and Meta-Analysis.
Zhu Y, Niu Y, Sun S, Liu W, Dou Y, Guo Y. · J Med Internet Res · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Ocular gene therapy targeting retinal angiogenesis and vascular leakage: translational and clinical evidence from a systematic review and meta-analysis.
Chen KY, Chan HC, Chan CM. · Angiogenesis · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Efficacy and Safety of Gene Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.
Chen KY, Chan HC, Chan CM. · Am J Ophthalmol · 2026 · cited 0 timesmeta-analysis, systematic review
- Clinical efficacy and safety of anti-VEGF biosimilars compared to reference anti-VEGF agents for neovascular age-related macular degeneration: a systematic review, meta-analysis, and meta-regression.
Al-Shammari YM, AlDhafiri YM, Ahmad AK, Alkharraz BB, Al-Awadhi MA, Alnabhan RM. · Int Ophthalmol · 2026 · cited 1 timesmeta-analysis, systematic review
- Obstructive sleep apnea and risk of age-related macular degeneration: A systematic review and meta-analysis.
Yaldo L, Ngo A, Yaldo M, Abdelaal A, Ong J, Kiryakoza L, Sengillo J. · Am J Ophthalmol · 2026 · cited 0 timesmeta-analysis, systematic review
- Radiotherapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.
Lei Y, Yang J, Li Y, Xiao B, Lai D, Qiu Q. · Curr Eye Res · 2026 · cited 0 timesmeta-analysis, systematic review
- Macular Neovascularization in Neovascular Age-Related Macular Degeneration: A Systematic Review of OCT Angiography-based Assessments and Challenges in Standardization.
Novarese C, Vyas C, Berni A, Bacherini D, Chaudhary V, Dolz-Marco R, Gallego-Pinazo R, Mastropasqua R, Reiter GS, Subhi Y, Bandello F, Reibaldi M, Borrelli E. · Ophthalmol Retina · 2026 · cited 0 timessystematic review, review
- Stereotactic radiotherapy for neovascular age related macular degeneration: year 3 and 4 extended follow up results of a randomised, double masked, sham controlled, device trial (STAR).
Jackson TL, Desai R, Wafa HA, Lee CN, Wang Y, Peacock JL, Peto T, Chakravarthy U, Zhu X, Dakin H, Wordsworth S, Clinch P, Ramazzotto L, Neffendorf JE, O'Sullivan JM, Reeves BC, STAR study group. · BMJ · 2026 · cited 1 timesOpen accessmulticenter study, randomized controlled trial
- Different aflibercept regimens for wet age-related macular degeneration: A systematic review and network meta-analysis.
Chen YS, Chang HC, Chi SC, Tanaka K, Chen SJ, Lin TC. · J Chin Med Assoc · 2026 · cited 0 timesOpen accesssystematic review, network meta-analysis
- Can MicroRNAs serve as reliable biomarkers and novel therapeutic targets in age-related macular degeneration? A systematic review and meta-analysis.
Chen KY, Chan HC, Chan CM. · J Transl Med · 2026 · cited 5 timesOpen accessmeta-analysis, research support, non-u.s. gov't
- Genetic determinants of age-related macular degeneration in Middle Eastern populations: a systematic review.
Sannan NS. · Front Genet · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial.
Chang A, Sun X, Iida T, Lai TYY, Wong TY, Cheung CMG, Lee WK, Zhang X, Schulze A, Schmidt-Ott UM, Zhao M, Hasanbasic Z, Leal S, Chen SJ, PULSAR study investigators. · Asia Pac J Ophthalmol (Phila) · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- Lost to Follow-Up in Neovascular Age-Related Macular Degeneration: A Systematic Review of Global Trends, Risk Factors, and Clinical Consequences.
Spooner KL, Fraser-Bell S, Mehta H, Hong T, Broadhead G, Wong JG, Chang AA. · Ophthalmologica · 2026 · cited 1 timesmeta-analysis, systematic review
- The Effect of Resveratrol, Quercetin, and Curcumin on Drusen Volume in Age-Related Macular Degeneration: A Randomized Clinical Trial.
Pfahler NM, Knepper PA. · Transl Vis Sci Technol · 2026 · cited 0 timesOpen accessclinical trial, phase ii, randomized controlled trial
- Efficacy of Faricimab in Neovascular Age-Related Macular Degeneration: A Single-Arm Systematic Review and Meta-Analysis.
Karam M, Baeshen M, Alfuzaie R, Mohammad M, Alshatti A, Samet A, Paez-Escamilla M, Sun V. · Ophthalmic Res · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Ranibizumab biosimilars vs. reference Ranibizumab for neovascular age-related macular degeneration: a systematic review and meta-analysis.
Rodrigues Alves N, Silva PB, Barão C, Costa L, Donato H, Basílio A, Flores R, Anjos R. · Graefes Arch Clin Exp Ophthalmol · 2025 · cited 0 timesmeta-analysis, systematic review
- Comparative efficacy and safety of Ranibizumab and Aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis.
Zhao X, Yang Y. · BMC Ophthalmol · 2026 · cited 0 timesOpen accessmeta-analysis, comparative study
- A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Lim JI, Leng T, Siedlecki J, Lupidi M, Wells JA, Keane PA, Nudleman E, Mar F, Gibson K, Margaron P, Tabano D, Bührer C, Holekamp N. · Ophthalmic Res · 2026 · cited 0 timesOpen accessother, comparative study
- Community Optometrist-Led Monitoring of Quiescent Neovascular Age-Related Macular Degeneration: The FENETRE Randomized Clinical Trial.
Sharma A, Jaber A, Pal B, Lawrenson JG, Harper RA, Tufail A, Learoyd AE, Robinson E, Douiri A, Burman R, Kernohan A, Vougioukalou S, Read S, Csontos J, Jones A, Mahmood S, McKibbin M, Peacock JL, Gale R, Patel PJ, Keane PA, Hamilton R, Vale L, Bunce C, Balaskas K. · JAMA Netw Open · 2026 · cited 0 timesOpen accessequivalence trial, research support, non-u.s. gov't
- Prognostic Factors in Patients With Submacular Haemorrhage Complicating Age-Related Macular Degeneration: A Post Hoc Analysis of the STAR Study.
Gabrielle PH, Eid P, Aho LS, Kodjikian L, Souied E, Uzzan J, Conart JB, Delyfer MN, Creuzot-Garcher C. · Clin Exp Ophthalmol · 2026 · cited 1 timesmulticenter study, randomized controlled trial
- PULSAR: Clinical Outcomes of Aflibercept 8 mg with Extended Dosing and 2 mg in Neovascular Age-Related Macular Degeneration in Subgroups Defined by Baseline Characteristics.
Gale RP, Loewenstein A, Zhang X, Leal S, Machewitz T, Sivaprasad S, Wong DT, Zeitz O, Korobelnik JF, PULSAR study investigators. · Ophthalmol Retina · 2026 · cited 1 timesclinical trial, phase iii, multicenter study
- Clinical Efficacy of Switching to Faricimab in Treatment Resistant Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-analysis.
Zhang C, Aboukasm G, Lai DA, Leung N, Zhu D, Albini TA, Yannuzzi NA. · Am J Ophthalmol · 2025 · cited 3 timesmeta-analysis, systematic review
- Global research trends and hotspots in the pathophysiology, imaging and therapy of type 3 macular neovascularization (MNV3) in age-related macular degeneration (AMD).
Li Y, Fu X, Huang L, Xiao L, Chen D. · Front Med (Lausanne) · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.